LT3079688T - Chromono darinys, kaip dopamino d3 receptoriaus antagonistas, skirtas panaudoti autizmo spektro sutrikimo gydymui - Google Patents

Chromono darinys, kaip dopamino d3 receptoriaus antagonistas, skirtas panaudoti autizmo spektro sutrikimo gydymui

Info

Publication number
LT3079688T
LT3079688T LTEP14812465.4T LT14812465T LT3079688T LT 3079688 T LT3079688 T LT 3079688T LT 14812465 T LT14812465 T LT 14812465T LT 3079688 T LT3079688 T LT 3079688T
Authority
LT
Lithuania
Prior art keywords
dopamine
treatment
receptor antagonist
autism spectrum
spectrum disorder
Prior art date
Application number
LTEP14812465.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Agnes Auclair
Paul Moser
Pierre Sokoloff
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of LT3079688T publication Critical patent/LT3079688T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP14812465.4T 2013-12-13 2014-12-12 Chromono darinys, kaip dopamino d3 receptoriaus antagonistas, skirtas panaudoti autizmo spektro sutrikimo gydymui LT3079688T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13
PCT/EP2014/077635 WO2015086836A1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder

Publications (1)

Publication Number Publication Date
LT3079688T true LT3079688T (lt) 2018-02-12

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14812465.4T LT3079688T (lt) 2013-12-13 2014-12-12 Chromono darinys, kaip dopamino d3 receptoriaus antagonistas, skirtas panaudoti autizmo spektro sutrikimo gydymui

Country Status (29)

Country Link
US (1) US10028948B2 (enExample)
EP (1) EP3079688B1 (enExample)
JP (1) JP6419826B2 (enExample)
KR (1) KR102280530B1 (enExample)
CN (1) CN105792824B (enExample)
AU (1) AU2014363428B2 (enExample)
BR (1) BR112016012552A8 (enExample)
CA (1) CA2932791C (enExample)
CY (1) CY1119907T1 (enExample)
DK (1) DK3079688T3 (enExample)
ES (1) ES2657706T3 (enExample)
HR (1) HRP20180323T8 (enExample)
HU (1) HUE036035T2 (enExample)
IL (1) IL245996B (enExample)
LT (1) LT3079688T (enExample)
MA (1) MA39076A1 (enExample)
MX (1) MX372922B (enExample)
MY (1) MY172937A (enExample)
NO (1) NO3079688T3 (enExample)
NZ (1) NZ720868A (enExample)
PL (1) PL3079688T3 (enExample)
PT (1) PT3079688T (enExample)
RS (1) RS56931B1 (enExample)
RU (2) RU2019104946A (enExample)
SA (1) SA516371298B1 (enExample)
SI (1) SI3079688T1 (enExample)
TN (1) TN2016000213A1 (enExample)
UA (1) UA117271C2 (enExample)
WO (1) WO2015086836A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2317852T1 (sl) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2021048544A1 (en) * 2019-09-11 2021-03-18 Oxford Biodynamics Limited Diagnostic chromosome marker
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
PE20001088A1 (es) * 1998-10-08 2000-12-02 Smithkline Beecham Plc Compuestos derivados de tetrahidrobenzazepina
ES2367868T3 (es) * 2004-09-20 2011-11-10 Mount Sinai School Of Medicine Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
KR101921772B1 (ko) * 2011-05-13 2018-11-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
FR2976179A1 (fr) 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
CN105792824A (zh) 2016-07-20
CY1119907T1 (el) 2018-06-27
HRP20180323T1 (hr) 2018-04-06
JP6419826B2 (ja) 2018-11-07
EP3079688A1 (en) 2016-10-19
AU2014363428A1 (en) 2016-06-23
HK1223563A1 (zh) 2017-08-04
WO2015086836A1 (en) 2015-06-18
TN2016000213A1 (en) 2017-10-06
RU2686110C1 (ru) 2019-04-24
BR112016012552A8 (pt) 2022-11-08
KR102280530B1 (ko) 2021-07-21
KR20160088886A (ko) 2016-07-26
DK3079688T3 (da) 2018-01-29
JP2016540000A (ja) 2016-12-22
SA516371298B1 (ar) 2018-06-07
NZ720868A (en) 2022-04-29
SI3079688T1 (en) 2018-03-30
IL245996B (en) 2018-11-29
IL245996A0 (en) 2016-07-31
CA2932791A1 (en) 2015-06-18
AU2014363428B2 (en) 2019-09-12
HRP20180323T8 (hr) 2019-01-25
MX372922B (es) 2020-04-27
CN105792824B (zh) 2018-08-03
PL3079688T3 (pl) 2018-05-30
RS56931B1 (sr) 2018-05-31
US20160303117A1 (en) 2016-10-20
UA117271C2 (uk) 2018-07-10
MY172937A (en) 2019-12-16
US10028948B2 (en) 2018-07-24
RU2019104946A (ru) 2019-04-01
ES2657706T3 (es) 2018-03-06
NO3079688T3 (enExample) 2018-04-21
MA39076A1 (fr) 2017-05-31
EP3079688B1 (en) 2017-11-22
HUE036035T2 (hu) 2018-06-28
MX2016007612A (es) 2016-09-09
CA2932791C (en) 2021-11-09
PT3079688T (pt) 2018-02-28

Similar Documents

Publication Publication Date Title
GB2520150B (en) Adjustable bed
GB2520430B (en) Adjustable bed
SG11201508717VA (en) Bed apparatus
GB201411935D0 (en) Early entry
GB201319060D0 (en) Early entry
PL3730035T3 (pl) Urządzenie okulistyczne
SG10201708406SA (en) Bed apparatus
PL2868431T3 (pl) Przestawianie agregatu
IL245996A0 (en) A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder
GB201310163D0 (en) Early entry
EP3021122A4 (en) DEVICE FOR SUPPLYING MEASURING CONTAINERS
PT3007725T (pt) Beta-glicolípidos para utilização como adjuvantes
EP2970319A4 (en) 6-ACETYLMORPHINE ANALOGUE AND METHOD FOR THE SYNTHESIS AND USE
ZA201601645B (en) Bendamustine pharmaceutical compositions
EP2948129A4 (en) THERAPEUTIC COMPOUNDS
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB201321961D0 (en) Early Entry
GB201313580D0 (en) Early entry
IL242794A0 (en) Metabolized benzoxazoles
GB201320905D0 (en) Therapeutic compounds
GB201301993D0 (en) Toolkits
GB201304666D0 (en) Dopamine receptor antagonist
AU351831S (en) Kiosk
AU351674S (en) Kiosk